Clinical trial
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
NCT00206518 · Mothaffar Rimawi, Other · Completed
Key facts
| NCT number | NCT00206518 |
|---|---|
| Title | Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients |
| Official title | A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation |
| Acronym | TACAC |
| Lead sponsor | Mothaffar Rimawi, Other |
| Collaborators | Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Taxotere/Docetaxel, Adriamycin/Cytoxan, doxorubicin |
| Enrollment | 167 |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2016 |
| Completion | Oct 10, 2016 |
| First posted | Sep 21, 2005 |
| Last update posted | Jul 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: